-
"In order to respond to an increased global demand, we plan to manufacture two billion doses of our Covid-19 vaccine in 2021 by expanding the previously expected output of 1.3 billion doses by more than 50 per cent," BioNTech said in a statement
-
In a yet-to-be peer reviewed research, scientists from the University of Texas Medical Branch, tested the ability of blood serum from 20 individuals immunised with the Pfizer-BioNTech vaccine to neutralise coronavirus engineered to carry the new mutations
-
The approval to Covaxin has been questioned by industry experts and some opposition Congress leaders who have expressed concern over the absence of phase 3 trial data
-
The Spanish branch of Pfizer informed Madrid on Sunday night of the delay in shipments to the eight nations due to a "problem in the loading and shipment process" at its plant in Belgium, the health ministry said in a statement.
-
In a virtual press conference this week, Sahin spoke about the potential virus deadline when asked when life could return to normal.
-
We're grateful for all the scientists, researchers, manufacturing workers, and service members, who have worked tirelessly to make this breakthrough possible. It is truly a Christmas miracle, said the US president
-
A person with knowledge of the negotiations told The Associated Press on Tuesday that the deal is under discussion but has not been finalised.
-
The novel coronavirus has mutated before, and both companies say they've found that their vaccines worked against other variations of the virus
-
The European Union is under massive pressure to approve potential vaccines after Britain and the United States began rolling out a drug produced by Pfizer and BioNtech.
-
In the past week, the US, the worst-hit nation, has reported an average of more than 215,000 new infections a day.
-
New SARS-CoV-2 variant raises questions over efficacy of vaccines
-
Frontline nurse Sandra Lindsay was administered the shot developed by Pfizer and its German partner BioNTech, in Long Island Jewish Medical Center in Queens Monday.
-
Bahrain plans to inoculate everyone 18 years and older in the kingdom at 27 different medical facilities, hoping to be able to vaccinate 10,000 people a day.
-
With northern hemisphere countries hit by a pandemic winter surge, Britain this week became the first Western country to roll out the Pfizer-BioNTech vaccine.
-
Pfizer's mRNA technology-based vaccine has an efficacy of over 90 per cent with a double dose and 67 per cent with a single dose. It, however, requires minus 70 degrees Celsius, which does not match India's cold storage facilities.
-
The UK will be the first country in the world to start using the Pfizer vaccine after regulators approved its use last week.
-
Priority groups will include care home residents, health and care staff, the elderly and the clinically extremely vulnerable.
-
The bill, which says the government will cover all vaccine costs for Japan's 126 million residents, was approved by the upper house of parliament, having cleared the powerful lower house.
-
The move comes a day after rival Moderna said it was asking US and European regulators to allow emergency use of its COVID-19 vaccine.
-
Latest figures on Tuesday showed that the country had recorded a total of 259,600 Covid deaths and 12.5 million cases -- with over 2,000 deaths and 167,000 new cases in just the last 24 hours.